| Literature DB >> 28461300 |
Michael R Edwards1, Sejal Saglani1, Jurgen Schwarze2, Chrysanthi Skevaki3, Jaclyn A Smith4, Ben Ainsworth5, Mark Almond1, Evangelos Andreakos6, Maria G Belvisi1, Kian Fan Chung1, William Cookson1, Paul Cullinan1, Catherine Hawrylowicz7, Marek Lommatzsch8, David Jackson1, Rene Lutter9, Benjamin Marsland10, Miriam Moffatt1, Mike Thomas5, J Christian Virchow8, Georgina Xanthou6, Jessica Edwards11, Samantha Walker11, Sebastian L Johnston12.
Abstract
Asthma is a heterogeneous, complex disease with clinical phenotypes that incorporate persistent symptoms and acute exacerbations. It affects many millions of Europeans throughout their education and working lives and puts a heavy cost on European productivity. There is a wide spectrum of disease severity and control. Therapeutic advances have been slow despite greater understanding of basic mechanisms and the lack of satisfactory preventative and disease modifying management for asthma constitutes a significant unmet clinical need. Preventing, treating and ultimately curing asthma requires co-ordinated research and innovation across Europe. The European Asthma Research and Innovation Partnership (EARIP) is an FP7-funded programme which has taken a co-ordinated and integrated approach to analysing the future of asthma research and development. This report aims to identify the mechanistic areas in which investment is required to bring about significant improvements in asthma outcomes.Entities:
Mesh:
Year: 2017 PMID: 28461300 DOI: 10.1183/13993003.02448-2016
Source DB: PubMed Journal: Eur Respir J ISSN: 0903-1936 Impact factor: 16.671